Document:

EX-10.10.4

 Exhibit 10.10.4 

AMENDMENT #2 
 TO

 PROJECT RIDER #1 

COLLABORATION AGREEMENT 
 This Amendment
#2 to Project Rider #1 (“Amendment #2”) is entered into effective as of the date of the final signature executing this Amendment #2 (“Amendment #2 Effective Date”) by and between Magenta Therapeutics, Inc.
(“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”) (each a “Party” and collectively the “Parties”). 

WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017 and a Project Rider, effective December 6, 2017 (as amended by
that certain Amendment #1, effective December 6, 2018, “Project Rider #1”); and 
 WHEREAS, the Parties agree to revise the Payment
Schedule of the Project Rider #1. 
 NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB
agree to the following amendment to be effective as of the Amendment #2 Effective Date as follows: 
 Amendment to Project Rider #1 

 

	 	1.	 Delete the Payment Schedule in Section D. Compensation of BTMB of Project Rider #1 in its
entirety and replace it with the following to read as follows: 

 PAYMENT SCHEDULE 

 

			
	For Services provided by BTMB during Calendar Year 2020 (January 1, 2020 through December 31, 2020), Magenta will pay BTMB a fixed price quarterly payment of $25,000.	  	 BTMB will invoice
$25,000 every January 15th for consulting services occurring during the period commencing January 1st and ending March 31st.
  
 BTMB will invoice $25,000 every
April 15th for consulting services commencing April 1st and ending June 30th.

 
 BTMB will invoice $25,000 every July 15th for consulting services commencing July 1st and ending September 30th.

 
 BTMB will invoice $25,000 every October 15th for consulting services commencing October 1st and ending
December 31st.

 [Remainder of page intentionally left blank.] 

 This Amendment #2 is executed by individuals who are duly authorized to legally bind their respective
parties as of the Amendment #2 Effective Date: 
  

									
	MAGENTA THERAPEUTICS, INC.	 		 	NATIONAL MARROW DONOR PROGRAM d/b/a BE THE MATCH BIOTHERAPIES
					
	By:	 	/s/ Christina Isacson	 		 	By:	 	/s/ Mary Frey
		 	Authorized signature	 		 		 	Authorized signature
					
		 	Christina Isacson	 		 		 	Mary Frey
		 	(Typed/Printed Name)	 		 		 	(Typed/Printed Name)
					
	Title:	 	Chief Business Officer	 		 	Title:	 	Contracts & Procurement Department
	Date:	 	November 13, 2019	 		 	Date:	 	11/12/19

  
 2EX-10.10.5

 Exhibit 10.10.5 

AMENDMENT #3 
 TO

 PROJECT RIDER #1 

COLLABORATION AGREEMENT 
 This Amendment
#3 to Project Rider #1 (“Amendment #3”) is entered into effective as of the date of the final signature executing this Amendment #3 (“Amendment #3 Effective Date”) by and between Magenta Therapeutics, Inc.
(“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”) (each a “Party” and collectively the “Parties”). 

WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017 and a Project Rider, effective December 6, 2017 (as amended by
that certain Amendment #1, effective December 6, 2018 and Amendment #2, effective November 13, 2019, “Project Rider #1”); and 

WHEREAS, the Parties agree to extend the Term and Payment Schedule of the Project Rider #1. 

NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB agree to the following amendment as
follows: 
 Amendment to Project Rider #1 
  

	1.	 Delete the Payment Schedule in Section D. Compensation of BTMB of Project Rider #1 in its
entirety and replace it with the following to read as follows: 

 PAYMENT SCHEDULE 

 

			
	For Services provided by BTMB during Calendar Year 2021 (January 1, 2021 through December 31, 2021), Magenta
will pay BTMB a fixed price quarterly payment of $17,500.	  	 BTMB will invoice
$17,500 every January 15th for consulting services occurring during the period commencing January 1st and ending March 31st.
  
 BTMB will invoice $17,500 every
April 15th for consulting services commencing April 1st and ending June 30th.

 
 BTMB will invoice $17,500 every July
15th for consulting services commencing July 1st and ending September 30th.

 
 BTMB will invoice $17,500 every October
15th for consulting services commencing October 1st and ending December
31st.

	2.	 Delete Section E. TERM. of Project Rider #1 in its entirety and replace it with the following to read as
follows: 

 E. TERM. The term of this Rider shall commence on the Rider effective date set forth above
and continue and remain in effect through December 31, 2021. 
 [Remainder of page intentionally left blank.] 

  
 2 

 This Amendment #3 is executed by individuals who are duly authorized to legally bind their respective
parties as of the Amendment #3 Effective Date: 
  

									
	MAGENTA THERAPEUTICS, INC.	 		 	 NATIONAL MARROW DONOR

PROGRAM d/b/a BE THE MATCH

BIOTHERAPIES

					
	By:	 	/s/ Christina Isacson	 		 	By:	 	/s/ Mary Frey
		 	Authorized signature	 		 		 	Authorized signature
					
		 	 Christina Isacson
	 		 		 	 Mary Frey

		 	(Typed/Printed Name)	 		 		 	(Typed/Printed Name)
					
	Title:	 	 Chief Business Officer
	 		 	Title:	 	 Contracts & Procurement Director

					
	Date:	 	 12/16/20
	 		 	Date:	 	 12/7/2020

  
 3EX-10.10.7

 Exhibit 10.10.7 

AMENDMENT #1 

COLLABORATION AGREEMENT 
  

 
 This Amendment #1 (“Amendment #1”)
is issued pursuant to the Collaboration Agreement (“Agreement”), effective November 10, 2017, between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match BioTherapies
(“BTMB”) and incorporates all of the terms and conditions therein. The effective date of this Amendment shall be December 31, 2020. 

The Parties agree to extend the term under the Agreement as follows: 

Replace Section 2. Term in its entirety to read as follows: 

2. Term. The term of this Agreement shall commence on the effective date set forth above and continue and remain in effect until
December 31, 2022 or until this Agreement is terminated as provided for in Section 9, “Termination”. 
 Except as provided above, all
other terms and conditions in the Agreement remain unchanged and in full force and effect. This Amendment #1 is executed by individuals who are authorized to bind their respective parties. 

 

									
	NATIONAL MARROW DONOR
PROGRAM d/b/a BE THE MATCH
BIOTHERPAIES	 		 	MAGENTA THERAPEUTICS, INC.
					
	By:	 	/s/ Mary Frey	 		 	By:	 	/s/ Christina Isacson
		 	Authorized signature	 		 		 	Authorized signature
					
		 	Mary Frey	 		 		 	Christina Isacson
		 	(Typed/Printed Name)	 		 		 	(Typed/Printed Name)
					
	Title:	 	Contracts & Procurement Director	 		 	Title:	 	Chief Business Officer
					
	Date:	 	12/7/2020	 		 	Date:	 	12/14/2020EX-10.14.2

 Exhibit 10.14.2 

SECOND AMENDMENT TO SUBLEASE AGREEMENT 

This SECOND AMENDMENT TO SUBLEASE AGREEMENT (this “Second Amendment”) is dated as of August 19, 2020 (the “Effective Date”) by
and between NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., a Delaware corporation, having an address at 100 Technology Square, Cambridge Massachusetts 02139 (“Novartis”), and MAGENTA THERAPEUTICS, INC., a Delaware
corporation, having an address at 50 Hampshire Street, 8th Floor, Cambridge Massachusetts 02139 (“Subtenant”). 

Background 

A.    Pursuant to a Lease, dated as of April 25, 2002, between ARE- Tech Square, LLC, as
successor in interest to Massachusetts Institute of Technology (“Overlandlord”), as landlord, and Novartis, as tenant, Overlandlord demised and let unto Novartis, and Novartis did hire and take from Overlandlord, the entire building known
by the street address of 100 Technology Square, Cambridge Massachusetts (the “Building”), on the terms and subject to the conditions set forth therein as amended by the First Amendment To Lease dated as of May 3, 2005, Second
Amendment to Lease dated as of June 24, 2010, Third Amendment To Lease date January 31, 2017, and Fourth Amendment To Lease dated as of May 14, 2018 (said Lease, as so amended, being referred to herein as the “Overlease”);
and 
 B.    Pursuant to the terms of that certain Sublease dated as of May 4, 2018 between Novartis, as sublandlord, and
Subtenant, as subtenant, as modified by that certain First Amendment To Sublease Agreement dated as of December 13, 2018 (collectively the “Original Sublease”), Novartis subleased the entire fifth (5th) Floor and the entire sixth (6th) Floor of the Building to Subtenant (the “Sublease Premises”). 

C.    Novartis and Subtenant desire to amend the Original Sublease in accordance with the terms of this Second Amendment. 

Agreement 
 NOW, THEREFORE, in
consideration of the covenants and conditions hereinafter set forth and for other good and valuable consideration, Novartis and Subtenant do hereby mutually covenant and agree as follows: 

1.    Definitions. Capitalized terms used in this Second Amendment and not otherwise defined herein shall have the meanings
assigned to them in the Original Sublease. The Original Sublease as amended by this Second Amendment is hereafter referred to as the “Sublease.” 

2.    Amendments. The Sublease is amended as follows: 
  

	 	(a)	 As of the Effective Date, the parties hereby agree that (i) the second (2nd) grammatical sentence in Section 6(a)(i) of the Original Sublease, beginning “Provided, however, no Space User shall be permitted...” shall hereafter be deleted and of no further
force and effect. The parties acknowledge those Space Users existing in portions of the Sublease Premises as of the Effective Date, namely Cellarity, Inc. (f/k/a: VL49, Inc.) and 

 
AvroBio, Inc., shall be entitled to extend their sub-subleases of those portions of the Sublease Premises that each occupies, pursuant to a sub-sublease agreement, and that the Initial Sublet/License Period shall be extended for any period up to and including April 30, 2022. 
  

	 	(b)	 As of the Effective Date, Subtenant agrees that Novartis has satisfied all of its obligations under
Section 15(e) of the Original Sublease (as modified by the First Amendment) including, without limitation, the obligation to pay the Sublet Improvement Allowance to Subtenant in full and that Novartis has no further liabilities or
obligations to Subtenant under Section 15(e) of the Original Sublease (as modified by the First Amendment). 

3.    General Provisions. 

(a)    Governing Law. The exercise, validity, construction, operation and effect of the terms and provisions of
this Second Amendment to Sublease Agreement shall be determined and enforced in accordance with the laws of the Commonwealth of Massachusetts applicable to agreements made and to be performed in the Commonwealth of Massachusetts. IN ANY ACTION OR
PROCEEDING ARISING HEREFROM, NOVARTIS AND SUBTENANT HEREBY BY CONSENT TO: (A) THE JURISDICTION OF ANY FEDERAL, STATE, COUNTY OR MUNICIPAL COURT SITTING IN THE COMMONWEALTH OF MASSACHUSETTS; (B) SERVICE OF PROCESS BY ANY MEANS AUTHORIZED BY
MASSACHUSETTS LAW; AND (C) IN THE INTEREST OF SAVING TIME AND EXPENSE, TRIAL WITHOUT A JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER OR THEIR SUCCESSORS IN RESPECT OF ANY MATTER ARISING
OUT OF OR IN CONNECTION WITH THIS SUBLEASE, THE RELATIONSHIP OF NOVARTIS AND SUBTENANT, SUBTENANT’S USE OR OCCUPANCY OF THE SUBLEASE PREMISES, AND/OR ANY CLAIM FOR INJURY OR DAMAGE, OR ANY EMERGENCY OR STATUTORY REMEDY. 

(b)    Authority. The parties hereto represent and warrant to each other that each has full right and authority to
enter into this Second Amendment and that the person signing this Second Amendment on behalf of each has the requisite authority for such act. 

(c)    Entire Agreement. This Second Amendment constitutes the entire agreement between the parties hereto and may
not be modified except by a written instrument executed by the parties hereto. 
 (d)    Captions. Paragraph
headings are used herein solely for reference purposes and are not to be construed as part of this Second Amendment. 

(e)    Counterparts and Execution. This Second Amendment may be executed and delivered in several counterparts,
each of which, when so executed and delivered, shall constitute an original, fully enforceable counterpart for all purposes. To facilitate execution of this Second Amendment, the parties hereto may execute and exchange, by electronic mail PDF,
counterparts of the signature pages. Signature pages may be detached from the counterparts and attached to a single copy of this Second Amendment to physically form one document. Each individual executing this Second Amendment on behalf of Novartis
or Subtenant represents and warrants that he or she has been duly authorized to do so. 

  
 2 

 (f)    Subordination to Prime Lease. 

This Second Amendment to Sublease is and shall be expressly subject and subordinate to all of the terms, provisions, covenants, agreements and conditions of
the Overlease. This Second Amendment to Sublease is also subject and subordinate to all instruments, agreements and other matters to which the Overlease is or shall be subject or subordinate. 

(g)    Full Force and Effect. Except as expressly modified herein or inconsistent with the terms hereof, the Sublease
shall remain in full force and effect and all of the provisions thereof are hereby ratified and confirmed. 

(h)    Broker. Novartis and Subtenant each represents to the other that it has not dealt with any brokers or agents with
respect to this Second Amendment to Sublease and each shall indemnify and hold harmless the other from and against any and all liabilities, claims, suits, demands, judgments, costs and expenses to which it may be subject or suffer by reason of any
claim made by any person, firm or corporation for any commission, expense or other compensation as a result of the execution and delivery of this Second Amendment to Sublease and based on alleged conversations or negotiations by said person, firm or
corporation with either Novartis or Subtenant, as the case may be. 
 [The remainder of this page intentionally left blank.] 

  
 3 

 IN WITNESS WHEREOF, Novartis and Subtenant have executed this Second Amendment to Sublease
Agreement as of the day and year first above written. 
  

			
	 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.,

A Delaware Corporation

		
	By:	 	/s/ Revathi Rommohan
		 	 Name: Revathi Rommohan
 Title: Chief
Financial Officer
 20-Aug-20 | 7:16:07 PM GMT

  

			
	 MAGENTA THERAPEUTICS, INC.,
 A
Delaware corporation

		
	By:	 	/s/ Jason Gardner
		 	 Name: Jason Gardner
 Title: CEO Magenta

19-Aug-20 | 6:34:31 PM EDT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]